ANIMATION

HuLuc 63

Share this animation:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO

Client


PDL BioPharma

Both the quality of the final product and my experience working with XVIVO has reinforced my interest in a long-term collaboration with this team.

Alain Viel PhD, Senior Lecturer and Director of Undergraduate Research in Molecular and Cellular Biology, Harvard University
Share this animation: